Urteste S.A. (URT.WA)
PLN 84.0
(0.0%)
PLN 84.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -6.44 Million PLN | -56.1% |
| 2022 | -4.13 Million PLN | -77.91% |
| 2021 | -2.32 Million PLN | -337.0% |
| 2020 | -531.2 Thousand PLN | -45.64% |
| 2019 | -364.73 Thousand PLN | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -2.47 Million PLN | -58.9% |
| 2024 Q2 | -609 Thousand PLN | 75.38% |
| 2023 Q4 | -1.55 Million PLN | 6.6% |
| 2023 Q1 | -1.45 Million PLN | -24.59% |
| 2023 Q2 | -1.76 Million PLN | -21.6% |
| 2023 Q3 | -1.66 Million PLN | 5.71% |
| 2023 FY | -7.77 Million PLN | -88.31% |
| 2022 Q1 | -963.94 Thousand PLN | -27.27% |
| 2022 FY | -4.13 Million PLN | -77.91% |
| 2022 Q4 | -1.16 Million PLN | -48.85% |
| 2022 Q3 | -784 Thousand PLN | 33.45% |
| 2022 Q2 | -1.17 Million PLN | -22.21% |
| 2021 Q4 | -757.4 Thousand PLN | -16.7% |
| 2021 Q3 | -649 Thousand PLN | -168.41% |
| 2021 Q2 | -241.79 Thousand PLN | 56.4% |
| 2021 Q1 | -554.55 Thousand PLN | 0.0% |
| 2021 FY | -2.32 Million PLN | -337.0% |
| 2020 Q2 | -238.58 Thousand PLN | 0.0% |
| 2020 FY | -531.2 Thousand PLN | -45.64% |
| 2019 FY | -364.73 Thousand PLN | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bioceltix S.A. | -15.81 Million PLN | 59.247% |
| BIOTON S.A. | 15.29 Million PLN | 142.151% |
| Captor Therapeutics Spolka Akcyjna | -73.01 Million PLN | 91.17% |
| Mabion S.A. | 55.06 Million PLN | 111.709% |
| Molecure S.A. | -22.1 Million PLN | 70.833% |
| NanoGroup S.A. | -7.9 Million PLN | 18.412% |
| Pharmena S.A. | 34.87 Million PLN | 118.488% |
| Poltreg S.A. | -16.86 Million PLN | 61.766% |
| Pure Biologics Spólka Akcyjna | -31.71 Million PLN | 79.674% |
| Ryvu Therapeutics S.A. | -100.94 Million PLN | 93.614% |
| Synthaverse S.A. | 8.64 Million PLN | 174.558% |